BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
KEYTRUDA (pembrolizumab) by Merck & Co. is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2014.
Drug data last refreshed 15h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEYTRUDA (pembrolizumab) is a monoclonal antibody that blocks the Programmed Death Receptor-1 (PD-1), unleashing the immune system to attack cancer cells. It is approved across multiple solid and hematologic malignancies and represents a cornerstone of modern immuno-oncology therapy. The mechanism works by inhibiting the PD-1/PD-L1 checkpoint interaction, restoring anti-tumor T-cell function.
$0.117BPart D
PeakPeak-stage asset with established market presence generating substantial Part D volume; expect mature commercial infrastructure and focus on lifecycle extension through combinations and new indications.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
Started Dec 2026
27 enrolled
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+10 more
Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer
Started Sep 2026
17 enrolled
Anal Squamous Cell Carcinoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Started Sep 2026
45 enrolled
Head and Neck Squamous Cell CarcinomaHPV-Negative Squamous Cell Carcinoma
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Started Sep 2026
150 enrolled
Head and Neck Squamous Cell Carcinoma
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants
Started Sep 2026
940 enrolled
Non-Small Cell Lung Cancer
Worked on KEYTRUDA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.